top of page

Price

chg

chg neg

quotes and stock data may be delayed 15 minutes

 My Notes

Only BPIQ Pro members can create company notes. Learn more here.

52 wk low

low api

52 wk hi

high api

Cash

$187.9M

Burn Rate (Qtr)

$31.4 M

Mkt Cap

mkt cap api

Avg Volume

volume api

*cash/burn updated:

Q1 '22

Drug Pipeline

Click the button to see the updated pipeline

No drug found

We don't have any drug data for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

Drug Name

Indication

Phase

Event

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Loading Catalysts...

search in progress

Pipeline powered by

AFMD

BPIQ_Logo_RGB-01.jpg

Company Profile

At Affimed, we are committed to improving outcomes for patients with cancer. Our scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unique approach to fighting cancer. With our unparalleled expertise in innate immunity and innate cell engager-based medicines, we aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.

Recent Posts

See what the community is saying - click to see full post.

11 smid-cap cancer companies with huge readouts in September 2024

11 smid-cap cancer companies with huge readouts in September 2024

Over 20 Smid-Cap Biopharmas Presenting at AACR 2023!

December 2022 Big Mover™ Stocks and Movers to Watch Report

The American Society of Hematology Annual Meeting 2022 - Investor Hub

Which smid-cap biopharmas are presenting exciting data at SITC 2022?

bottom of page